Shares in many large drugmakers initially fell Wednesday on the president's threat, only to rebound later when he announced a ...

Global drugmakers and MedTech companies bounced back after U.S. President Donald Trump issued a 90-day pause on reciprocal ...

It is with great honor that the Chester County Opportunities Industrialization Centers (Chester County OIC) welcomes its ...

Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

Vertex Pharmaceuticals Inc. closed 8.54% short of its 52-week high of $519.88, which the company achieved on November 8th.

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about ...

Will these developments be enough to sustain the rally? Let's discuss whether Vertex Pharmaceuticals stock is a buy now. The past year has been transformative for Vertex, marked by the launch of ...

Morgan Stanley raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $462 from $459 and keeps an Equal Weight rating on the ...

The stock's rise snapped a three-day losing streak.

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...